.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Chubb
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
Cantor Fitzgerald
Medtronic
Dow
Julphar
Federal Trade Commission

Generated: July 20, 2017

DrugPatentWatch Database Preview

RISPERDAL Drug Profile

« Back to Dashboard

What is the patent landscape for Risperdal, and what generic Risperdal alternatives are available?

Risperdal is a drug marketed by Janssen Pharms and is included in four NDAs. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-four patent family members in twenty-seven countries.

The generic ingredient in RISPERDAL is risperidone. There are thirty drug master file entries for this compound. Fifty-eight suppliers are listed for this compound. Additional details are available on the risperidone profile page.

Summary for Tradename: RISPERDAL

Patents:1
Applicants:1
NDAs:4
Suppliers / Packagers: see list6
Bulk Api Vendors: see list82
Clinical Trials: see list93
Patent Applications: see list5,666
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RISPERDAL at DailyMed

Pharmacology for Tradename: RISPERDAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo6,596,316*PED► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo5,916,598*PED► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo6,667,061*PED► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo6,194,006*PED► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET, ORALLY DISINTEGRATING;ORAL021444-001Apr 2, 2003ABRXYesNo6,224,905*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RISPERDAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-008May 10, 19995,158,952*PED► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-003Dec 29, 19935,158,952*PED► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET, ORALLY DISINTEGRATING;ORAL021444-003Apr 2, 20034,804,663*PED► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-005Dec 29, 19934,804,663*PED► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET, ORALLY DISINTEGRATING;ORAL021444-003Apr 2, 20035,648,093*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: RISPERDAL

Drugname Dosage Strength RLD Submissiondate
risperidoneOrally Disintegrating Tablets0.25 mgRisperdal4/11/2005
risperidoneOrally Disintegrating Tablets3 mg and 4 mgRisperdal3/23/2005

International Patent Family for Tradename: RISPERDAL

Country Document Number Estimated Expiration
Norway321510► Subscribe
Estonia03549► Subscribe
Estonia9800428► Subscribe
Spain2172793► Subscribe
South Africa9705277► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RISPERDAL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0008Belgium► SubscribePRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
US Department of Justice
Johnson and Johnson
Citi
Chubb
Daiichi Sankyo
AstraZeneca
Julphar
Chinese Patent Office
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot